Spectrum reports encouraging results from ZEVALIN study Pharmaceutical Business Review The standard-dose ibritumomab tiuxetan combined with BEAM high-dose chemotherapy is safe and effective than BEAM alone as conditioning regimen for ASCT in the era of rituximab-containing chemotherapy regimens. The company will expand clinical ... ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive ... |
